Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...
Axios on MSN19m
Signs of optimism for biopharma at JPM conference
After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...